Vendor security reviews · Digital health & life sciences
Vendor Security Review & Questionnaire Support for Biotech & Pharma Companies
Vendor security review for a biotech or pharma company runs in the opposite direction from most companies' experience of it: instead of answering a customer's questionnaire, the company is the one qualifying its CROs, PSP hubs, central labs and cloud vendors. The trigger is usually onboarding a new hub for a patient support program, negotiating a CRO's master service agreement, or reviewing existing vendors after a hub-services breach elsewhere in the industry made the risk concrete. We help the company ask the right questions of vendors who often hold the identifiable layer of data the company never sees itself.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
Which vendors carry the risk a biotech or pharma company has to qualify
The company's own systems are rarely where the deepest exposure sits; it sits with the third parties running the identifiable layer of trial and patient data.
CROs running EDC, eTMF and IRT systems
The contract research organizations operating the day-to-day trial systems that hold key-coded participant data and safety narratives on the sponsor's behalf.
PSP hubs and specialty pharmacies
The vendors most likely to hold fully identifiable patient enrolment, diagnosis and consent data, and the vendor category the industry's largest recent incident exposed most directly.
Central labs and genomic/biomarker vendors
Third parties processing sample manifests and biomarker or genomic data, often connected to the company's own LIMS through a data-exchange integration.
Cloud and SaaS platforms hosting validated systems
The infrastructure and application vendors behind eCTD publishing, ELN, LIMS and safety databases, most of it hosted outside Canada under its own compliance regime.
HCP and marketing-data vendors
CRM and marketing-cloud providers holding prescriber engagement and program mailing lists, a category that gets far less scrutiny than clinical vendors despite handling sensitive lists.
Regulatory map
Why the company stays accountable even when a vendor holds the data
Handing data to a third party does not hand off the legal responsibility that goes with it, in either privacy law or clinical-trial regulation.
PIPEDA's accountability for third-party transfers
An organization remains accountable for personal information it transfers to a vendor for processing, which is why the review has to happen before the contract is signed, not after something goes wrong.
Division 5 duties delegated by contract, not eliminated
A sponsor can delegate trial-related tasks to a CRO, but the good-clinical-practice and record obligations remain the sponsor's, which is exactly what a vendor security review has to confirm the CRO can actually support.
Quebec's vendor and subcontractor expectations
Where a program reaches Quebec residents, obligations extend to how vendors and their own subcontractors handle that data, which a review needs to trace beyond the immediate contract.
What goes wrong
What vendor security review is meant to catch before onboarding
Every scenario here is one where the company discovers, after the fact, that a vendor's actual practice fell short of what the relationship assumed.
A hub vendor breach exposing enrolled patients
A compromise at a patient support program hub can expose names, diagnoses and medications for a drug the sponsor manufactures, drawing scrutiny toward the sponsor even though the vendor operated the system.
A SOC 2 report that doesn't cover what matters
A vendor's SOC 2 report may attest to controls over an entirely different service boundary than the one actually handling your trial or PSP data, leaving a gap a surface-level review would miss.
Undisclosed sub-processors
A CRO or hub vendor's own subcontractors — a translation service, a courier, a secondary cloud host — can hold your data without ever appearing in the vendor's own marketing materials or standard questionnaire.
Cloud infrastructure outage cascading into trial systems
An incident at a shared eClinical or cloud provider can take multiple sponsors' trial systems offline at once, a concentration risk a vendor review should surface before the contract is signed.
Our vendor security reviews for biotech & pharma companies
What our vendor security review covers for a biotech or pharma company
Structured evaluation applied to the specific vendor types this sector depends on, rather than a generic third-party risk template.
Gap review of a prospective or current vendor's posture
An assessment of how a CRO, hub, lab or cloud vendor's actual practices compare with what the sensitivity of your data requires, before or after the relationship begins.
Guidance on what evidence to request by vendor type
Clarity on when a SOC 2 report, a security schedule, or a subcontractor disclosure list is the right thing to ask for, and how to read what comes back.
Control consideration matched to the data at stake
Focused attention on the controls that actually matter for the specific trial, PSP or lab data a vendor touches, rather than re-auditing everything a vendor's own certification already covers.
Ongoing oversight as vendor relationships evolve
Periodic re-review as a CRO expands its subcontractor list, a hub changes ownership, or a cloud vendor migrates infrastructure, so qualification doesn't happen only once at signing.
How the engagement runs
How we review a vendor for a biotech or pharma company
Weighted toward the vendors handling the most identifiable and highest-value data first.
Step 1
Tier the vendor
We classify each vendor by what it actually touches — identifiable PSP data, key-coded trial data, unfiled IP or general corporate information — since the review depth should match the stakes.
Step 2
Request and review evidence
SOC 2 reports, security schedules and subcontractor disclosures are requested and checked against what the vendor's actual role requires, not accepted at face value.
Step 3
Assess the gap against your data
We identify where a vendor's certification scope doesn't quite reach the specific systems or data flows your relationship depends on.
Step 4
Shape the contract's security schedule
Findings feed directly into the security terms negotiated in the CRO or hub agreement, so the review changes the contract, not just a file on record.
Step 5
Reassess periodically
Vendors are revisited on a schedule or after a material change, keeping qualification current rather than frozen at the signing date.
What it costs
What determines vendor security review cost for a biotech or pharma company
Cost depends on how many vendors need review, how critical each one is — a PSP hub holding identifiable patient data warrants deeper scrutiny than a general corporate SaaS tool — and whether the engagement includes shaping the actual contract security schedule.
A company with one CRO and no live PSP costs less to cover than one running several hub relationships, a central lab connection and a validated cloud stack at once. We scope pricing after identifying which vendors carry the most exposure in your specific environment.
Biotech & Pharma Companies: Vendor security reviews questions, answered
At minimum, a documented security schedule in the contract, evidence of the controls protecting identifiable patient or trial data specifically, a clear notification timeline if the vendor is breached, and disclosure of any subcontractors that also touch that data. A vendor unwilling to commit to any of these in writing is telling you something about how it would handle an actual incident.
Start from the vendor's SOC 2 report and identify what it actually covers, then focus your own review only on the gaps — the specific data flows, integrations or configurations the report doesn't address. Re-testing controls the vendor's own auditor already verified wastes effort better spent on what the certification doesn't reach.
It should specify the safeguards protecting enrolment and health data, breach-notification timelines to the sponsor that are fast enough to support the sponsor's own regulatory obligations, disclosure of any subcontractors involved, and audit or evidence rights so the sponsor isn't relying solely on the hub's own word between reviews.
Every vendor touching identifiable PSP data or trial-critical systems should go through some level of review; the depth should scale with the sensitivity of what they hold. A general office-software vendor rarely warrants the same scrutiny as a hub processing enrolment forms with diagnoses and medications.
It works best as ongoing oversight. A vendor qualified at signing can change its subcontractors, its infrastructure or its ownership within a year, and a review that never repeats leaves the company relying on assumptions that may no longer be true.
More for biotech & pharma companies
Other services for this niche
About this service
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.